MOTS-c: 2026 Mitochondrial Peptide Research

MOTS-c (mitochondrial open reading frame of the twelve S ribosomal RNA-c) is a mitokine—a signaling peptide encoded by mitochondrial DNA and secreted from mitochondria—that modulates metabolism and energy homeostasis. This article reviews MOTS-c's mechanism, 2026 preclinical evidence, and its regulatory pathway toward potential compounding eligibility.

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome (hence "mitochondrial-derived peptide" or MDP). Unlike most research peptides, it originates inside mitochondria and is secreted as a signaling molecule. MOTS-c was first identified at the University of Southern California in 2015 and has since become a focus of metabolic and longevity research. MOTS-c is not FDA-approved as a drug and remains strictly a research compound.

Mechanism: AMPK and metabolic sensing

MOTS-c's primary proposed mechanism involves:

• AMPK activation. AMP-activated protein kinase (AMPK) is a cellular energy sensor; activation prompts catabolic (energy-yielding) processes and suppresses anabolic (energy-consuming) processes. MOTS-c appears to activate AMPK.
• PGC-1α upregulation. Downstream of AMPK, the PGC-1α pathway enhances mitochondrial biogenesis and oxidative metabolism.
• Fat oxidation and glucose uptake. These effects support fatty acid combustion and improved insulin-stimulated glucose uptake in muscle.

2026 preclinical evidence: obesity and metabolism

Preclinical research demonstrates MOTS-c activity in multiple metabolic contexts:

• High-fat diet models. Mice treated with MOTS-c showed reduced fat-mass accumulation on high-fat diet without significant changes in food intake, indicating metabolic improvement rather than appetite suppression.
• Glucose metabolism. Improved fasting glucose and glucose tolerance in prediabetic and diet-induced obesity models.
• Hepatic steatosis. Reduced fatty liver (hepatic steatosis) in obesity models, a key metabolic dysfunction marker.
• Natural decline with age. Endogenous MOTS-c levels decrease with age and obesity, making peptide supplementation a potential intervention point.

2026 FDA and human trial status

FDA PCAC Review (July 23, 2026): MOTS-c was scheduled for FDA Pharmacy Compounding Advisory Committee review in July 2026 to evaluate potential addition to the 503A bulk substances list for obesity and osteoporosis applications.

Human Clinical Trials: A Phase 2a, randomized, placebo-controlled trial (NCT07505745) is recruiting and testing investigational MOTS-c in adults with prediabetes and overweight or obesity. However, as of August 2026, no completed human trial results have been published. Earlier human evidence is extremely limited.

Critical evidence gap: preclinical vs. clinical translation

Metabolic peptides have a historical pattern: promising preclinical data (especially in mouse models) does not always translate to humans. Key limitations:

• Preclinical models are simplified. Diet-induced obesity in rodents differs from complex human obesity and comorbidities.
• Bioavailability and stability. MOTS-c is a peptide; oral absorption is uncertain, and intravenous/injection delivery was used in animal studies.
• Effect size in humans may be smaller. Animal studies often show 20–30% fat loss; human trials, if efficacious, typically show 5–15% body-weight reduction.

MOTS-c research compound

We supply MOTS-c for preclinical research with full purity documentation:

View research peptides

Sources & further reading

• Spartan Peptides — MOTS-C Peptide 2026: Mitochondrial Signaling and Metabolic Research Guide
• SourcePeptides — MOTS-C Peptide Research Guide: Mechanisms and Preclinical Study Findings (2026)
• Restorative Compounding Pharmacy — MOTS-c Peptide: Metabolism, Exercise, Longevity & FDA Status

Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.